Molecular Pharmacology Program

The Hedvig Hricak Lab

Share
Back to top

Research

Hedvig Hricak, MD, PhD
Hedvig Hricak, MD, PhD
Carroll and Milton Petrie Chair

Professor

Our laboratory is working on establishing phenotypic signatures of cancer using multimodality anatomic and molecular imaging. We also aim to integrate multimodality imaging with anatomic pathology, genomics, and other molecular signatures to gain further insight into comprehensive molecular and anatomic tumor profiling. The goal is to further advance understanding of in vivo tumor biology and tumor heterogeneity (both spacial and temporal). We plan to develop and validate tumor biomarkers that can be used for treatment selection, assessment of treatment response or early detection of treatment resistance. Using advanced computational methods of radiomics and radiogenomics, we are evaluating how multimodality/multiplexing technology can advance our knowledge of tumor phenotypes and their associations with genomic mutations. We are also exploring targeted imaging and targeted therapies to ultimately expand the field of theranostics, which we believe is one of the future paths to precision medicine.

View Lab Overview

The Hedvig Hricak Lab

Featured News

In the Clinic
Pictured: Serge Lyashchenko
How Our New Particle Accelerator Will Make Cancer Imaging and Treatment More Precise

The launch of a 20-ton instrument and a facility for producing radioactive imaging molecules will allow our doctors and scientists to monitor cancers in unparalleled detail.
Announcement
Pictured: Jason Lewis, Anna-Katerina Hadjantonakis & Daniel Heller
Memorial Sloan Kettering Launches New Center for Molecular Imaging and Nanotechnology

The new center brings together scientists and clinicians working in various fields who will use the power of imaging to speed research and innovations in cancer care.
Hedvig Hricak (left) and David Scheinberg are members of the new Nanotechnology Center's executive committee, which Dr. Scheinberg chairs.
New Nanotechnology Center Combines Cutting-Edge Science with Memorial Sloan Kettering's Expertise in Patient Care

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.

View All Featured News

Publications

Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014 Apr;271(1):220-9. PubMed Central PMCID: PMC4263648. PubMed

Donati OF, Afaq A, Vargas HA, Mazaheri Y, Zheng J, Moskowitz CS, Hricak H, Akin O. Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score. Clin Cancer Res. 2014 Jul 15;20(14):3705-11. PubMed

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014 Sep;134(3):455-61. PubMed Central PMCID: PMC4387777. PubMed

Donati OF, Mazaheri Y, Afaq A, Vargas HA, Zheng J, Moskowitz CS, Hricak H, Akin O. Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology. 2014 Apr;271(1):143-52. PubMed

Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, Zheng J, Goldman D, Moskowitz C, Fine SW, Reuter VE, Eastham J, Sala E, Vargas HA. Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol. 2015 Oct;25(10):2840-50. PubMed Central PMCID: PMC5026307. PubMed

View All Publications

People

Hedvig Hricak, MD, PhD

Hedvig Hricak, MD, PhD

Carroll and Milton Petrie Chair

Professor

  • Radiologist Hedvig Hricak researches methodologies of molecular imaging of prostate and gynecologic tumors.
  • MD, University of Zagreb School of Medicine (Yugoslavia)
  • Dr. Med. Sc. Karolinska Institute (Sweden)
212-639-7284
Office Phone

Members

Vladimir Ponomarev
Vladimir Ponomarev

Associate Attending in the Radiochemistry and Imaging Sciences Service of the Department of Radiology

Amita Dave
Amita Dave

Director, Quantitative Imaging; and Deputy Service Chief Predictive Informatics in the Department of Medical Physics

Oguz Akin

Attending Radiologist, Director of Body MRI, Department of Radiology

Ida Haeggstroem
Ida Haeggstroem
Marius Erik Mayerhoefer

Attending Radiologist and is Director of PET/MRI in the Department of Radiology

Yousef Mazaheri

Attending in the Department of Medical Physics

Sungmin Woo

Assistant Attending Radiologist, Body Imaging Service, Department of Radiology

Lab Alumni
Jose Lobo

Senior Research Technician

Sarah M. Cheal

Research Fellow, R25T Molecular Imaging: Training for Oncology Program

Jason T. Lee

Research Fellow, R25T Molecular Imaging: Training for Oncology Program

Jason M. Samii

Fellow, R25T Molecular Imaging: Training for Oncology Program

Daniel Thorek

Research Fellow, R25T Molecular Imaging: Training for Oncology Program

Josip Ninčević

Research Fellow

Rikiya Yamashita

Research Fellow

Lab Affiliations

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Hedvig Hricak discloses the following relationships and financial interests:

  • Ion Beam Applications
    Fiduciary Role/Position
  • Paige.AI, Inc.
    Fiduciary Role/Position

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures